Pacheco Rafael L, Latorraca Carolina de Oliveira Cruz, de Souza Alexandre Wagner Silva, Pachito Daniela V, Riera Rachel
Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil.
Evidence Based Health Program, Universidade Federal de São Paulo, Sao Paulo, Brazil.
Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12993. Epub 2017 Sep 12.
Takayasu arteritis (TA) is a rare systemic vasculitis that affects large vessels often resistant to treatment and associated with high morbidity and mortality. Treatment is defied by the relapsing nature of the disease and frequent adverse effects of corticosteroids and immunosuppressors, rendering failure of treatment in a significant portion of patients. Considering the low quantity and quality of published studies focusing on treatment of TA, synthesis and critical assessment of the available evidence is fundamental to establish recommendations for clinical practice.
To evaluate the effectiveness and safety of clinical interventions for TA.
Systematic review conducted in accordance to recommendations stated in the Cochrane Handbook, with inclusion of all comparative studies focusing on any type of clinical intervention for TA.
Five comparative studies were included (one randomised clinical trial, two non-randomised clinical trials, and two historical cohorts) totalling 342 patients, aiming at the assessment of effectiveness of corticosteroids, immunosuppressors, biologics and other types of pharmacological treatment for distinct clinical presentations of TA. The quality of studies, assessed by the use of instruments developed specifically for each study design, was considered low. Data scarcity and clinical heterogeneity prevented quantitative synthesis (meta-analysis).
Despite an extensive literature search, few comparative studies with small sample sizes were retrieved. The quality of these studies was considered low, preventing recommendations on effectiveness and safety of the studied interventions for clinical practice. Until new comparative studies with more robust sample sizes are conducted, treatment of TA should be guided individually taking into account the severity of disease and the availability of treatment options.
大动脉炎(TA)是一种罕见的系统性血管炎,可累及大血管,通常对治疗耐药,且发病率和死亡率较高。疾病的复发性质以及皮质类固醇和免疫抑制剂频繁的不良反应给治疗带来了挑战,导致相当一部分患者治疗失败。鉴于聚焦TA治疗的已发表研究数量少且质量低,对现有证据进行综合和批判性评估对于制定临床实践建议至关重要。
评估TA临床干预措施的有效性和安全性。
按照Cochrane手册中的建议进行系统评价,纳入所有聚焦TA任何类型临床干预措施的比较研究。
纳入了五项比较研究(一项随机临床试验、两项非随机临床试验和两项历史性队列研究),共计342例患者,旨在评估皮质类固醇、免疫抑制剂、生物制剂和其他类型药物治疗对TA不同临床表现的有效性。通过使用专门为每种研究设计开发的工具评估,研究质量被认为较低。数据稀缺和临床异质性妨碍了定量综合分析(荟萃分析)。
尽管进行了广泛的文献检索,但仅检索到少量样本量较小的比较研究。这些研究的质量被认为较低,无法为临床实践中所研究干预措施的有效性和安全性提供建议。在开展样本量更大、更可靠的新比较研究之前,TA的治疗应根据疾病严重程度和治疗选择的可用性进行个体化指导。